# Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

> **NCT04407741** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** SHR2554+SHR1701
- **DRUG:** SHR1701

## Key facts

- **NCT ID:** NCT04407741
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04407741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04407741, "Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04407741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*